AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 NOV 14 - (NewsRx.com & NewsRx.net) -- The Biojector 2000 (B-2000) has been chosen by the Dale and Betty Bumpers Vaccine Research Center (VRC) as the delivery device for its first AIDS vaccine in human clinical testing. The B-2000 was developed by Bioject Medical Technologies (BJCT), which specializes in needle-free drug delivery systems. The VRC is part of the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH).
Participants will be given three 1 ml intramuscular injections in the upper arm with the B-2000 system, the only needle-free device cleared by the FDA to give intramuscular injections.
The VRC is described as a cross between a biotechnology company and an academic organization. It is the first facility at the NIH dedicated solely to vaccine research and production. The AIDS vaccine under testing was produced only one year after the newly constructed center opened.
"We are pleased to have been chosen by the NIH for delivery of its first AIDS vaccine and that we have progressed from various preclinical studies to reach this human clinical ...
Source: HighBeam Research, NIH Uses Bioject's Needle-Free Injection System For DNA AIDS Vaccine...